Biomea Fusion reported early clinical evidence that its experimental oral obesity drug BMF-650 can produce meaningful weight loss with relatively limited gastrointestinal side effects, giving the small biotech a potentially differentiated asset in the increasingly competitive market for GLP-1 medicines. The Phase 1 results were encouraging enough to support further development, but they stopped well short of establishing how the drug will perform over the longer treatment periods that matter most in obesity.
In the four outpatient multiple-dose cohorts of the GLP-131 study, participants receiving BMF-650 lost an average of 1.5% to 3.2% of their body weight after 29 days, compared with 0.1% among pooled placebo participants. At doses of at least 200 milligrams once daily, average weight loss was approximately 0.97 kilograms per week, according to Biomea.
The more important question for investors is whether BMF-650 can preserve that rate of weight loss while maintaining the tolerability profile Biomea designed the drug to achieve. Oral GLP-1 development has become increasingly competitive, and Biomea is entering the field after Eli Lilly’s orforglipron reached the U.S. market earlier this year. That raises the bar considerably: early evidence of efficacy alone is unlikely to differentiate a new oral GLP-1 without advantages in tolerability, dosing convenience, durability or some combination of the three.
Tolerability Is the Main Differentiation Biomea Is Trying to Establish
BMF-650 is a small-molecule GLP-1 receptor agonist that Biomea designed with the goal of limiting gastrointestinal exposure while preserving enough systemic activity to drive weight loss. Across the five active multiple-dose cohorts, involving 40 participants, all reported treatment-emergent adverse events were mild or moderate. There were no severe or serious treatment-emergent adverse events, no dose modifications attributed to adverse events and no treatment discontinuations for that reason.
Across those active-dose groups, nausea occurred in 17.5% of participants, vomiting in 7.5%, constipation in 10% and diarrhea in 5%. The company also reported no adverse events involving increased ALT or AST liver enzymes during the four-week treatment period. Those numbers are useful early signals, although a Phase 1 study of this size and duration cannot establish how the safety profile will hold up in a much larger population receiving the medicine for months or years.
Biomea also tested a faster dosing schedule intended to determine whether patients could reach a high dose without the prolonged titration schedules commonly used with GLP-1 therapies. Eight participants in a fifth cohort received 200 milligrams daily for one week before moving directly to 400 milligrams for the following three weeks. One participant experienced nausea and one experienced vomiting, representing 12.5% of the treatment group for each event, while two reported constipation and none reported diarrhea. All of those gastrointestinal events were Grade 1.
The company said those results justify evaluating whether BMF-650 could eventually be used with little or potentially no titration. That remains a development hypothesis rather than an established product advantage, however. Biomea will need longer trials before it can determine the dose regimen that balances weight loss, gastrointestinal tolerability and adherence.
The Highest-Dose Weight Loss Requires Caution
The fifth cohort produced the most dramatic efficacy number in the study, with participants receiving BMF-650 losing an average of 6.1% of their body weight, or about 6.2 kilograms, by Day 29. That translates to roughly 1.55 kilograms per week, with Biomea reporting no apparent slowing of weight loss during the four-week treatment period.
Those results cannot be interpreted the same way as the outpatient cohorts. Cohort 5 was conducted under confinement, and the two placebo participants experienced a similar degree of weight loss. Biomea said those placebo participants consumed only about one-third of the 2,100 calories of food made available to them each day, indicating that the controlled setting itself substantially affected eating behavior.
The company appropriately separated that cohort from the outpatient data rather than presenting the 6.1% figure as clean evidence of BMF-650’s drug effect. For evaluating efficacy, the 1.5% to 3.2% weight reductions observed across Cohorts 1 through 4 provide the more useful early signal. The fifth cohort is more informative for the company’s rapid-titration argument than for determining how much weight patients are likely to lose in ordinary clinical use.
That distinction may help explain the market’s skeptical response. Biomea shares closed regular trading Tuesday at $1.26, down 7.4%, before falling another 28.6% to about $0.90 in after-hours trading following the data release. The decline does not establish that investors rejected BMF-650 solely because of the trial results, but it shows that the readout did not immediately resolve concerns surrounding the program or the company’s broader financing position.
A Partner Could Become Important to BMF-650’s Future
Biomea does not currently appear prepared to push BMF-650 through late-stage development entirely on its own. The company said additional development after completion of Phase 1b will require longer-term toxicology work and that it intends to position BMF-650 for a strategic partnership, potentially including a licensing arrangement covering late-stage development and commercialization.
That strategy is financially relevant. Biomea ended June with $35.2 million in cash, cash equivalents and restricted cash and projected at the time that its existing resources would fund operations into the second quarter of 2027. The company recorded an $8.3 million net loss during the second quarter, while accumulated losses since inception had reached approximately $469.8 million.
Financing became an even more visible issue in September. Biomea attempted to launch a public securities offering on Sept. 22 but terminated it the following day, saying market conditions were not favorable enough to complete the transaction on terms management considered appropriate for shareholders. No securities were sold.
Finding a development partner for BMF-650 could therefore accomplish more than simply validate the asset scientifically. Depending on the structure, a licensing or collaboration agreement could shift part of the development expense to a larger pharmaceutical company and potentially provide upfront or milestone payments without requiring Biomea to finance the full program itself.
Biomea has also made clear that BMF-650 is not its primary development priority. Management said its main focus remains icovamenib, the company’s experimental menin inhibitor being developed for diabetes. The Phase 2 COVALENT-211 study is expected to produce 26-week data in insulin-deficient Type 2 diabetes during the first quarter of 2027, while the COVALENT-212 trial in patients inadequately controlled on GLP-1-based therapy is expected to report later in 2027.
For BMF-650, the next meaningful evidence will have to come from longer-duration studies that can determine whether the outpatient weight-loss trajectory continues and whether the low incidence of gastrointestinal side effects survives exposure to more patients over more time. Until then, the Phase 1 results give Biomea an asset with enough activity to justify further work, but the commercial case increasingly depends on proving that BMF-650 can offer something established oral GLP-1 therapies do not — and on securing the capital or partnership required to test that proposition properly.